Xylo
Private Company
Funding information not available
Overview
Xylo is a private, preclinical-stage biotech developing a novel class of small-molecule neuroplastogens, or psychedelic-inspired therapeutics, designed to promote neuroplasticity without the hallucinogenic effects associated with classical psychedelics. The company combines computational drug design and advanced neuroscience to target specific serotonin receptors, aiming to create accessible, next-generation treatments for major psychiatric conditions. Following a rebrand from Psylo and an $8 million Series Seed financing in 2024, Xylo has established a US corporate structure and is building a pipeline focused on precision neurotherapeutics. Its experienced team and distinguished scientific advisory board position it to advance its programs toward clinical development.
Technology Platform
Computational drug discovery and medicinal chemistry platform for designing novel small molecules (neuroplastogens) that target specific serotonin receptors to enhance neuroplasticity while minimizing hallucinogenic and other undesirable effects.
Opportunities
Risk Factors
Competitive Landscape
Xylo competes in a rapidly evolving field with companies like Delix Therapeutics, Gilgamesh Pharmaceuticals, and Atai Life Sciences' non-hallucinogenic programs, all developing next-generation psychedelic-inspired therapeutics. Differentiation will depend on the specific pharmacological profile, clinical efficacy, and safety data of its candidates.